Abstract
Background and Aim:
The prognostic potential of cardiac troponin (cTn) in acute stroke patients has been a subject of ongoing debate. Our objective was to provide a comprehensive evidence for predicting mortality in acute stroke patients by using the elevated troponin levels.
Methods:
We conducted an extensive literature search, including PubMed, EMbase, and Trip Databases, covering studies published up to September 30, 2023. We computed risk ratios (RR) with 95% confidence intervals (CIs), performed sensitivity analysis, and conducted trial sequential analysis (TSA).
Results:
In total, 53 studies were analyzed, with 37 focusing on acute ischemic stroke (AIS), 11 on subarachnoid hemorrhage (SAH), and 7 on Intracerebral hemorrhage (ICH). Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RR=3.80, 95% CI; 2.82 to 5.12) as well as SAH (RR=2.23, 95% CI; 1.64 to 3.02). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RR=1.13, 95% CI: 0.46 to 2.79). A similar pattern was observed for elevated cTn levels, indicating an increased risk of last follow-up mortality for AIS (RR=2.41, 95% CI: 1.98 to 2.93) and SAH (RR=3.08, 95% CI: 2.25 to 4.21).
Conclusion:
Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.
Introduction
Acute stroke represents a critical medical condition with substantial implications for patient outcomes and healthcare systems (1). In this context, the timely and accurate identification of prognostic markers capable of predicting stroke-associated mortality emerges as a paramount imperative (2). Such markers not only facilitate risk assessment but also guide precise and targeted clinical interventions, ultimately influencing patient outcomes and optimizing healthcare resource allocation (3). Cardiac Troponin (cTn), widely recognized as a cardinal biomarker in cardiology, has recently attracted attention for its potential role as an indicator of mortality risk in patients afflicted by acute stroke (4).
In the short term, the immediate post-stroke period, in-hospital mortality rates for acute stroke patients can exhibit alarming elevations, with figures occasionally reaching a staggering 50% (5). The major driving force behind such acute fatalities often lies in cardiac-related complications. These complications manifest through the release of cardiac troponin-T (cTnT), cardiac troponin-I (cTnI), High-sensitive cardiac Troponin I (hs-cTnI) and High-sensitive cardiac Troponin T (hs-cTnT) proteins into the circulatory system. Importantly, during the acute phase of ischemic stroke (IS), a marked elevation in serum levels of cTnT or cTnI is frequently observed, establishing a robust link between cardiac injury and the stroke itself (6). The precise and timely prognosis of this cardiac involvement not only impacts therapeutic strategies but also plays a pivotal role in the monitoring and management of patient outcomes, fundamentally shaping the quality of healthcare delivery (7).
However, despite the potential of cardiac troponin as a prognostic marker, the scientific literature presents contrasting findings regarding its association with the risk of all-cause mortality in patients afflicted with acute stroke (8). Moreover, the precision of risk estimates demonstrates considerable variability across individual research studies. Troponin elevations have been reported in a substantial proportion of stroke patients, with prevalence rates ranging from 27% to 34% (9). These elevations have been consistently linked to heightened mortality in various stroke subtypes, encompassing IS, Intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). Nevertheless, previous meta-analyses (6, 10ā17) have failed to definitively establish troponin elevation as an independent and unequivocal prognostic factor in the context of acute stroke patients. As a result, the debate concerning the predictive utility of elevated cardiac troponin levels in the stroke population continues to be a subject of scientific scrutiny. Therefore, we aimed to conduct a systematic review and meta-analysis, aptly named āElevated Troponin Levels as a Mortality Predictor in Acute Stroke,ā in order to explore the utility of cTn in predicting mortality following acute stroke.
Methods
Search strategy
The Cochrane Handbook (version 5.1.0) was used to conduct a systematic review and meta-analysis (18). The preferred reporting items for systematic reviews and meta-analyses (PRISMA) were followed throughout the systematic reviewās creation (19). Electronic searches were conducted in databases including PubMed, EMbase, and Trip Databases up to 30th September 2023. Additionally, the reference list of retrieved studies and previous meta-analyses, was manually search for collecting more relevant studies often missed while performing the electronic search. The search aimed to identify studies the prediction of cTn level with the mortality rate in patient with acute stroke. The search utilized a set of specific keywords, including (āTroponinā OR āCardiac Troponinā OR ācTnTā OR ācTnIā OR āTroponin Iā OR āTroponin Tā OR āHigh Sensitive Troponinā OR āHigh Sensitive Troponin Iā OR āhTnIā OR āHigh Sensitive Troponin Tā OR āhTnTā) AND (āStrokeā OR āBrain Strokeā OR āAcute Strokeā OR āIschemic Strokeā OR āCerebral Infarctionā OR āIntracerebral Hemorrhageā OR āHemorrhagic Strokeā OR āSubarachnoid Hemorrhageā OR āAneurysmal Subarachnoid Hemorrhageā) AND (āMortalityā OR āMortality Rateā OR āDeathā OR āDeath Rateā OR āPrognosisā OR āOutcomeā).
Selection criteria
Published observational studies, including prospective cohort and retrospective cohort studies that investigate the predictive utility of Cardiac Troponin (cTn) as a biomarker for mortality in patients with acute stroke.
Studies that report data related to either in-hospital mortality and/or last follow-up mortality as endpoints.
Studies that provide data on cTn assay results at least for a single time point during the course of the study.
Studies involving human participants.
Case reports, case series, review articles, gray literature, and editorials.
Studies not reporting relevant outcomes.
Unavailability of full-texts.
Data extraction
Two independent authors (āAā and āMSā) conducted a meticulous evaluation of the identified articles to assess their eligibility for inclusion in our study. Upon the initial screening, the authors proceeded to a comprehensive examination of the full-text articles to validate their eligibility and to systematically extract relevant data. To facilitate this process, a standardized data extraction form was utilized, ensuring uniformity and thoroughness in data collection process. The following data was extracted from studies: First Authorās Name, Published year, Country, Study design, Study period, Sample size of elevated cTn and normal cTn groups, source, cTn cut-off value, cTn assessment time point, cTn type, cTn estimation method, In-hospital mortality, Last follow-up mortality outcome measured. The values of cTn levels were reported with different units in the included studies and were converted to similar units for analysis purpose using online unit conversion tools.1,2 Any disagreement were resolved through discussion with the corresponding author.
Quality assessment
The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for observational cohort studies (20). The NOS evaluates study quality across three domains: selection of participants, comparability of groups, and ascertainment of outcomes. Studies were assigned scores ranging from 0 to 9, with higher scores indicating higher quality. Any discrepancies in quality scores were resolved through consensus with the corresponding author.
Publication bias
To assess publication bias, we employed a funnel plot analysis (21). Eggerās regression test was used to ascertain the asymmetry of funnel plots (22).
Statistical analysis
A fixed/random-effects model was used to calculate the pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was calculated with the I2 statistic. The heterogeneity was considered as significant in case of I2 more than 50% for which random effects model was applied, on the other hand, if I2 was less than 50%, then fixed-effect model was applied. Sensitivity analysis was performed by sequentially omitting a single study in each turn, to validate the pooled observed effect. In order to ascertain the sufficiency of our sample size and the statistical power of our meta-analysis, we conducted Trial Sequential Analysis (TSA). Tests were considered statistically significant at a p-value less than 0.05. All statistical analyses were carried out using STATA, version 12.0 (Stata Statistical Software, Release 12; StataCorp LP, College Station, TX).
Results
Search results and study characteristics
Figure 1 illustrates the PRISMA flow diagram detailing the inclusion and exclusion criteria for studies in our systematic review and meta-analysis. Initially, 1,234 studies were identified across three databases and from other sources. After removing duplicates, 237 articles remained, and following further exclusions, 62 full-text articles were assessed for eligibility. Finally, 53 studies (23ā73) were included that examined the role of elevated troponin for predicting mortality in acute stroke. Among these studies, 37 studies focused on AIS patients (23ā59), 11 on SAH patients (28, 53, 60ā68), and 7 on ICH patients (28, 53, 69ā73). The AIS studies involved 3,606 patients with elevated troponin and 14,099 patients with normal troponin, the SAH studies involved 450 patients with elevated troponin and 980 patients with normal troponin, and the ICH studies involved 1,041 patients with elevated troponin and 1,259 patients with normal troponin. Geographically, 24 AIS studies were conducted in Caucasian regions (23ā38, 41, 42, 44, 49, 50, 53, 55, 56), and 13 in Asian regions (39, 40, 43, 45ā48, 51, 52, 54, 57ā59). For SAH, 10 studies were in Caucasian regions (28, 53, 60ā66, 68), with only 1 in an Asian region (67). In ICH, 4 studies were in Caucasian regions (28, 53, 69, 72), and 3 in Asian regions (70, 71, 73). Two studies (28, 53) were common for AIS, SAH, and ICH subjects. The publication years ranged from 2000 to 2023, and the sample sizes varied from 43 to 1,718, with detailed baseline characteristics provided in Table 1.
Figure 1
Table 1
| S. no. | References | Country | Study design | Study period | ETP(n) | NTP (n) | Cutoff value | cTn assessment timepoint | Type of cTn | Estimation method | Source | Last follow-up duration | Outcome measured |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute ischemic stroke | |||||||||||||
| 1. | James et al. (23) | New Zealand | PCS | July 1997āMarch 1998 | 30 | 151 | >0.1 ug/l | Within 72āh of symptom | cTnT | ELISA | Serum | NR | Troponin, mortality |
| 2. | Trooyen et al. (24) | Norway | PCS | January 1999āJune 1999 | 40 | 109 | >0.4āμg/L | Within 48āh of symptom | cTnI | MEIA | Serum | NR | Neurological outcomes, mortality |
| 3. | Angelontanio et al. (25) | Italy | PCS | February 2001āJanuary 2002 | 18 | 277 | >0.01āng/mL | Within 24āh of symptom | cTnI | RIA | NR | NR | Mortality, non-fatal MI event, non-fatal cardiopulmonary event |
| 4. | Barber et al. (26) | UK | PCS | NR | 45 | 177 | >0.2āμg/L | Within 24āh of symptom | cTnI | CIA | Serum | 30ādays | Death or dependency (Rankin > 2) |
| 5. | Jensen et al. (27) | Denmark | PCS | August 2003āOctober 2004 | 25 | 219 | >0.03āμg/L | Within 7ādays after symptom | hs-cTnT | ELISA | NR | 19āmonths | All-cause in-hospital mortality |
| 6. | Sandhu et al. (28) | USA | PCS | NR | 23 | 138 | >0.4āng/mL | Within 24āh of symptom | cTnI | NR | Serum | NR | In-hospital mortality |
| 7. | Hajdinjak et al. (29) | Slovenia | PCS | June 2006āMay 2010 | 16 | 90 | >0.04āμg/L | Within 24āh of symptom | cTnT | ELISA | NR | NR | In-hospital mortality |
| 8. | Scheitz et al. (30) | Germany | RCS | October 2009āOctober 2010 | 103 | 612 | >0.03āμg/L | Within 7ādays after symptom | cTnI | ELISA | NR | NR | Unfavorable outcome, Major neurologic improvement, In-hospital mortality |
| 9. | Jensen et al. (31) | USA | PCS | August 2003āOctober 2004 | 65 | 128 | >14āng/L | Within 24āh of symptom | hs-cTnT | CIA | NR | 4.4āyears | All-cause mortality |
| 10. | Boire et al. (32) | Canada | PCS | October 2006āNovember 2010 | 46 | 362 | >0.03 ug/L | Within 72āh of symptom | cTnI | NR | NR | 90ādays | Death, myocardial Infarction, mRS score, recurrent stroke |
| 11. | Stahrenberg et al. (33) | Germany | PCS | March 2009āFebruary 2010 | 98 | 99 | ā„6.15āpg./mL | Within 24āh of symptom | hs-cTnT | ELISA | Plasma | 12āmonths | Vascular events, all-cause mortality |
| 12. | Scheitz et al. (34) | Germany | PCS | February 2011āFeb ruary2013 | 308 | 409 | >14āng/L | Within 48āh of symptom | cTnT | ELISA | NR | NR | Unfavorable neurological outcome and in-hospital mortality |
| 13. | Lasek-Bal et al. (35) | Poland | PCS | 2013ā2014 | 104 | 964 | > 0.014āng/mL | Within 72āh of symptom | cTnI | ELISA | Serum | 30ādays | Mortality, mRS 4ā6 |
| 14. | Faiz et al. (36) | Norway | RCS | June 2009āMay 2010 | 156 | 131 | >14āng/L | within 24āh of symptom | hs-cTnT | ELISA | Serum | NR | In-hospital mortality |
| 15. | Raza et al. (37) | USA | RCS | 2008ā2010 | 17 | 183 | >0.40āng/mL | Within 24āh of symptom | cTnI | CIA | Serum | 2āyears | Long term cardiac adverse event, all cause death |
| 16. | Batal et al. (38) | USA | PCS | December 2008āNovember 2010 | 309 | 1,409 | >0.1āμg/L | Within 24āh of symptom | cTnI | CIA | Serum | 3āyears | Mortality |
| 17. | Maoz et al. (39) | Israel | RCS | 1āyear | 35 | 177 | >0.03āμg/L | NR | hs-cTnT | NR | Serum | NR | NIHSS and mortality |
| 18. | Su et al. (40) | Taiwan | RCS | August 2010āMarch 2015 | 146 | 725 | >0.01āμg/L | Within 48āh of symptom | cTnI | ELISA | Serum | NR | poor outcome and in-hospital mortality |
| 19. | Budincevic et al. (41) | Croatia | RCS | 2007ā2010 | 10 | 188 | >0.5 ug/L | Within 24āh of symptom | cTnI | NR | NR | NR | Unfavorable outcome, death |
| 20. | Peddada et al. (42) | USA | RCS | May 2008āDecember 2012 | 199 | 946 | >0.120āng/mL | Within 7ādays after symptom | cTnI | CIA | Serum | NR | NIHSS and mortality |
| 21. | Akpinar et al. (43) | Turkey | RCS | NR | 11 | 53 | >0.014āng/mL | Within 48āh of symptom | cTnT | CIA | Serum | Mean: 9.6ādays | In-hospital mortality |
| 22. | Wrigley et al. (44) | USA | RCS | 2010 | 295 | 1,082 | between 40 and 50āng/L | Within 24āh of symptom | cTnT and cTnI | NR | Serum | 3āYear | Long-term mortality, Structural cardiac disease |
| 23. | Ahn et al. (45) | Korea | RCS | May 2007āDecember 2014 | 166 | 1,526 | >0.04āng/mL | Within 48āh of symptom | cTnI | CMIA | Serum | 33āmonths | Long-term mortality |
| 24. | Fathy et al. (46) | Egypt | PCS | March 2016āDecember 2016 | 14 | 60 | >0.01āμg/L. | Within 48āh | cTnI | ELISA | Serum | NR | Poor short-term outcome and in-hospital mortality |
| 25. | He L. et al. (47) | China | RCS | May 2012āDecember 2017 | 118 | 398 | ā„14āng/L | Within 72āh | hs-cTnT | CIA | Serum | 3āmonths | Death, Major disability |
| 26. | Ahn et al. (48) | Korea | PCS | 2013ā2015 | 145 | 947 | ā„0.040āng/mL | Within 48āh | cTnI | CIA | Serum | 18āmonths | Adverse long-term outcomes, mortality |
| 27. | He M. et al. (49) | USA | RCS | January 2013āDecember 2016 | 25 | 58 | 0.6āng/mL | Within 48āh | cTn | NR | NR | 1āyear | All-cause mortality, AMI, AIS, and all-cause re-hospitalization |
| 28. | Terceno et al. (50) | Spain | PCS | NR | 42 | 68 | ā„14āng/L | Within 24āh of symptom | hs-cTnT | NR | Plasma | 3āmonths | Mortality, mRS, NIHSS |
| 29. | Sui et al. (51) | China | PCS | January 2017āFebruary 2018 | 65 | 176 | >14āng/L | Within 24āh of symptom | hs-cTnT | NR | Serum | 90ādays | Mortality, disability |
| 30. | Cao et al. (52) | China | RCS | January 2015āNovember 2017 | 85 | 58 | >14āng/L | Within 48āh of symptom | hs-cTnT | CIA | Serum | 3āmonths | Poor outcome and mortality |
| 31. | Alkhachroum et al. (53) | USA | RCS | January 2013āApril 2015 | 197 | 621 | >0.04āng/mL | Within 48āh of symptom | cTnI | NR | Serum | NR | Disease severity, mortality, functional outcome and discharge disposition |
| 32. | Thapa et al. (54) | Nepal | PCS | NR | 8 | 93 | > 0.034āng/mL | Within 48āh of symptom | hs-cTnI | CIA | Serum | NR | Poor outcomes and in-hospital mortality |
| 33. | Scheitz et al. (55) | Germany | PCS | January 2010āJune 2013 | 220 | 342 | >14āng/L | Within 7ādays of symptom | hs-cTnT | CIA | Serum | 3āyear | Recurrent stroke, myocardial infarction, and all-cause death |
| 34. | Nageeb et al. (56) | Egypt | PCS | January 2017āJanuary 2019 | 13 | 59 | ā„0.01āμg/L | Within 24āh after onset | cTnI | ELISA | Serum | 3āmonths | Death, disability, neurological improvement |
| 35. | Miraj et al. (57) | Bangladesh | PCS | NR | 8 | 92 | >0.04āng/mL | Within 7ādays after symptom | cTnI | NR | Serum | NR | Poor outcome and in-hospital mortality |
| 36. | Chen et al. (58) | China | PCS | February 2016āNovember 2020 | 90 | 264 | >0.03ug/L | within 24āh after onset | hs-cTnI | CIA | NR | 90ādays | hscTnI, mortality |
| 37. | Kim et al. (59) | Korea | RCS | August 2014āJuly 2017 | 311 | 708 | 20.7āng/L for men and 16.1āng/L for women | within 24āh of symptom | hs-cTnI | CIA | NR | 22.5āmonths | Mortality and cardiac and cerebrovascular events |
| Subarachnoid hemorrhage | |||||||||||||
| 38. | Deibert et al. (60) | USA | PCS | January 1998āAugust 2000 | 12 | 31 | ā„1.4 ug/L | On admission | cTnI | NR | Serum | NR | Home, acute rehabilitation, nursing home and death |
| 39. | Naidech et al. (61) | USA | PCS | November 1998āOctober 2002 | 46 | 81 | >0 to 0.5 ug/L | On admission | cTnI | NR | Serum | 3āmonths | Functional disability or death |
| 40. | Sandhu et al. (28) | USA | PCS | NR | 20 | 76 | >0.4āng/mL | On admission | cTnI | NR | Serum | NR | In-hospital mortality |
| 41. | Ramappa et al. (62) | USA | PCS | January 1999āDecember 2003 | 31 | 52 | ā„2.0āng/mL | On admission | cTnI | NR | Serum | NR | Worse neurological outcome and in-hospital mortality |
| 42. | Gupte et al. (63) | USA | RCS | August 2006āJune 2009 | 47 | 157 | >0.5āng/mL | On admission | cTnI | NR | NR | NR | In-hospital mortality |
| 43. | Duello et al. (64) | USA | RCS | March 2011āJuly 2013 | 36 | 139 | >0.10āng/mL | On admission | cTnT | NR | NR | 1āmonth | Mortality |
| 44. | Guette et al. (65) | France | PCS | October 2012āAugust 2015 | 76 | 61 | >22āng/L | within 72āh of symptom onset | hs-cTnT | ELISA | Plasma | 3āmonths | Sensitivity and specificity with corresponding 95% CIs. |
| 45. | Alkhachroum et al. (53) | USA | RCS | January 2013āApril 2015 | 48 | 75 | >0.04āng/mL | On admission | cTnI | NR | Serum | NR | Disease severity, Mortality, functional outcome and discharge disposition |
| 46. | Akkermans et al. (66) | Netherland | PCS | November 2005āFebruary 2008 | 43 | 116 | >12āng/L | NR | cTnI | NR | Serum | 1āyear | Myocardial infarction, cardiac death, all-cause mortality |
| 47. | Lin et al. (67) | China | PCS | January 2016āDecember 2017 | 55 | 158 | >0.016āng/mL | On admission | cTnI | NR | NR | 34.3āmonths | Major adverse cardiac events, long-term neurological outcomes, and mortality |
| 48. | Anetsberger et al. (68) | Germany | PCS | March 2013āDecember 2015 | 36 | 34 | >0.007āμg/L | On admission | cTnT | ELISA | NR | 3āmonths | Functional outcome and mortality |
| Intracerebral hemorrhage | |||||||||||||
| 49. | Hays et al. (69) | USA | RCS | January 2001āJanuary 2005 | 38 | 84 | >0.10āng/mL | within 24āh | cTnI | RIA | Serum | NR | In-hospital mortality |
| 50. | Sandhu et al. (28) | USA | PCS | NR | 14 | 80 | >0.4āng/mL | within 24āh | cTnI | NR | Serum | NR | In-hospital mortality |
| 51. | Chung et al. (70) | South Korea | RCS | January 2003āDecember 2007 | 28 | 225 | >0.01āng/mL | Within 24 admission hours | cTnT | ELISA | Serum | NR | In-hospital mortality |
| 52. | Xu et al. (71) | China | RCS | NR | 66 | 122 | NR | NR | cTnI | NR | NR | NR | In-hospital mortality, GCSā<ā8, NIHSS >10 |
| 53. | Gerner et al. (72) | Germany | PCS | 2006ā2014 | 83 | 437 | >0.040āng/mL | Within 72āh after admission | cTnI | CIA | Plasma | NR | Functional outcome |
| 54. | He et al. (73) | China | RCS | June 2012āDecember 2015 | 729 | 88 | ā„0.028āng/mL | NR | cTnI | CIA | Serum | NR | In-hospital mortality and mRS |
| 55. | Alkhachroum et al. (53) | USA | RCS | January 2013āApril 2015 | 83 | 223 | >0.04āng/mL | On admission | cTnI | NR | Serum | NR | Disease severity, mortality, functional outcome and discharge disposition |
Baseline characteristics for the included studies investigating for elevated Troponin level in predicting mortality for acute stroke patients.
RCS, Retrospective Cohort Study; PCS, Prospective Cohort Study; cTnI, Cardiac troponin I; cTnT, Cardiac troponin T; hs-cTnT, High-sensitive cardiac Troponin T; hs-cTnI, High-sensitive cardiac Troponin I; NIHSS, National Institute of Health Stroke Scale; GCS, Glasgow Coma Scale; mRS, Modified Rankin Scale; NR, not reported; ELISA, enzyme-linked immunosorbent assay; CIA, chemiluminescence immunoassay; RIA, radioimmunoassay; MEIA, Microparticle Enzyme Immunoassay; CMIA, chemiluminescent microparticle immunoassay.
Regarding predictive mortality outcomes, 15 studies with AIS patients (23ā25, 28ā30, 34, 36, 39ā43, 54, 57), 6 with SAH (28, 53, 60, 62, 63, 67), and 7 with ICH (28, 53, 69ā73) reported data for In-hospital mortality. For last follow-up mortality, 22 AIS studies (26, 27, 31ā35, 37, 38, 44ā53, 56, 58, 59) and 6 SAH studies (61, 64ā68) provided relevant data. Only a single study (67) reported data both In-hospital mortality and last follow-up mortality for SAH subjects. The majority of studies included in our review received high ratings on the NOS Scale, indicating strong methodological quality (Table 2). Each studyās total score, ranging from 6 to 9, reflects its overall quality, supporting the reliability and validity of the evidence presented in this review.
Table 2
| Selection | Comparability | Outcome | Result | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S. no. | References | Representative of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome was not present at study start | Comparability of cohorts based on design or analysis | Assessment of outcome | Enough follow up period | Adequacy of follow up | Total score |
| Acute ischemic stroke | ||||||||||
| 1. | James et al. (23) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
| 2. | Trooyen et al. (24) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 3. | Angelontanio et al. (25) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 4. | Barber et al. (26) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 5. | Jensen et al. (27) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 6. | Sandhu et al. (28) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 7. | Hajdinjak et al. (29) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 8. | Scheitz et al. (30) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 9. | Jensen et al. (31) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | |
| 10. | Boire et al. (32) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 11. | Stahrenberg et al. (33) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 12. | Scheitz et al. (34) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 13. | Lasek-Bal et al. (35) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 14. | Faiz et al. (36) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 15. | Raza et al. (37) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 16. | Batal et al. (38) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | |
| 17. | Maoz et al. (39) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 18. | Su et al. (40) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 19. | Budincevic et al. (41) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 20. | Peddada et al. (42) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 21. | Akpinar et al. (43) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
| 22. | Wrigley et al. (44) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 23. | Ahn et al. (45) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 24. | Fathy et al. (46) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 25. | He L. et al. (47) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | |
| 26. | Ahn et al. (48) | 1 | 1 | 1 | 2 | 1 | 1 | 7 | ||
| 27. | He M. et al. (49) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 28. | Terceno et al. (50) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 29. | Sui et al. (51) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 30. | Cao et al. (52) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 31. | Alkhachroum et al. (53) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 32. | Thapa et al. (54) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 33. | Scheitz et al. (55) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 34. | Nageeb et al. (56) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 35. | Miraj et al. (57) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 36. | Chen et al. (58) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 37. | Kim et al. (59) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Subarachnoid hemorrhage | ||||||||||
| 38. | Deibert et al. (60) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| 39. | Naidech et al. (61) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
| 40. | Sandhu et al. (28) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 41. | Ramappa et al. (62) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 |
| 42. | Gupte et al. (63) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 43. | Duello et al. (64) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 44. | Guette et al. (65) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 45. | Alkhachroum et al. (53) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 46. | Akkermans et al. (66) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| 47. | Lin et al. (67) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 48. | Anetsberger et al. (68) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Intracerebral hemorrhage | ||||||||||
| 49. | Hays et al. (69) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 50. | Sandhu et al. (28) | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| 51. | Chung et al. (70) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 52. | Xu et al. (71) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 53. | Gerner et al. (72) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 54. | He et al. (73) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
| 55. | Alkhachroum et al. (53) | 1 | 1 | 1 | 1 | 2 | 1 | 7 | ||
Quality assessment of included studies based on Newcastle-Ottawa Scale (NOS).
In-hospital mortality
Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RRā=ā3.80, 95% CI; 2.82 to 5.12; Figure 2A) as well as SAH (RRā=ā2.23, 95% CI; 1.64 to 3.02; Figure 2B). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RRā=ā1.13, 95% CI: 0.46 to 2.79; Figure 2C).
Figure 2
Further subgroup analysis based on type of cTn, study design, Troponin cut-off value, and estimation method of troponin showed diverse patterns. Specifically for AIS subgroup analysis based on type of troponin, cTnI had a higher prediction risk (RR: 3.93; 95% CI: 2.34 to 6.60) than cTnT (RR: 3.63; 95% CI: 2.24 to 5.88) and hs-cTnT (RR: 3.34; 95% CI: 1.32 to 8.47) while hscTnI had (RR: 6.40; 95% CI: 1.21 to 33.88; Supplementary Table S1A). Based on study design, prospective cohort studies (PCS) had a higher risk (RR: 4.00; 95% CI: 2.43 to 6.57) compared to retrospective cohort studies (RCS) [RR: 3.66; 95% CI: 2.45 to 5.47]. Troponin cut-off values also showed variation, with 0.01 to 0.05āμg/L at RR: 4.55 (95% CI: 3.29 to 6.29) and 0.1 to 0.5āμg/L at RR: 2.86 (95% CI: 1.70 to 4.83). Assessment time-points within 24, 48, and 72 h had different risks.
The choice of troponin estimation methods significantly influenced risk, with Enzyme-Linked Immunosorbent Assay (ELISA) resulting in RR: 3.56 (95% CI: 2.07 to 6.12), Radioimmunoassay (RIA) at RR: 4.57 (95% CI: 2.23 to 9.34), and chemiluminescence immunoassay (CIA) at RR: 2.92 (95% CI: 2.16 to 3.96). Prediction risks varied at assessment time-points within 24, 48, and 72āh, but stability was observed for studies examining troponin levels within 24āh after Acute Ischemic Stroke (AIS). For SAH patients, subgroup analysis for showed that cTnI had a higher predictive risk for In-hospital mortality (RRā=ā2.23; 95% CI: 1.64 to 3.02). Both PCS (RRā=ā2.31; 95% CI: 1.49 to 3.58) and RCS (RRā=ā2.15; 95% CI: 1.40 to 3.31) also showed higher predictive role of elevated troponin for the In-hospital mortality in SAH patients (Supplementary Table S1B). For ICH, subgroup analysis revealed non-significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (Supplementary Table S1C). Only significant association for the assessment time point of troponin levels within 24āh and within 48āh after ICH (RRā=ā1.76; 95% CI: 1.01 to 3.06) and (RRā=ā3.05; 95% CI: 1.17 to 7.91) respectively were observed (Supplementary Table S1C).
Last follow-up mortality
Elevated cTn levels were also significantly showed a higher predictive risk for last follow-up mortality in both AIS (RRā=ā2.41, 95% CI: 1.98 to 2.93; Figure 3A) and SAH (RRā=ā3.08, 95% CI: 2.25 to 4.21; Figure 3B). Subgroup analysis showed hs-cTnT stood out with a significantly higher prediction risk (RR: 6.02; 95% CI: 2.60 to 13.93) in AIS, compared to cTnT and cTnI (Supplementary Table S2A). Both prospective and retrospective study designs, indicated an elevated predictive role of elevated troponin for last follow-up mortality in AIS and SAH subgroup analysis (Supplementary Tables S2A,B). Predictive risk remained stable for studies examining troponin levels within 24āh after AIS and SAH. Troponin estimation methods varied for AIS studies, with most utilizing CIA method, while for SAH, the predominant method was ELISA. Analysis on last follow-up mortality in ICH group was not feasible as only a single study provided data for it.
Figure 3
Publication bias
Funnel plot analysis did not reveal any apparent signs of asymmetry. The distribution of studies around the estimated effect appeared to be even, suggesting the absence of significant publication bias that could impact the results. Funnel plots for the in-hospital mortality in patients with AIS (p =ā0.45), SAH (p =ā0.10), and ICH (p =ā0.19), and last follow-up mortality for AIS (p =ā0.13), and SAH (p =ā0.42), are represented in Supplementary Figures S1AāC, S2A,B.
Sensitivity analysis
Sensitivity analysis indicated that the pooled risk estimates for in-hospital mortality in patients with AIS, SAH, and ICH was not significantly affected by the removal of any individual study (Supplementary Figures S3AāC). Similarly, the pooled risk estimates for last follow-up mortality in patients with AIS and SAH was not significantly affected by the removal of any individual study (Supplementary Figures S4A,B). Our findings suggest that the results of the meta-analysis are robust and are not driven by any single study which provides additional confidence in the validity of the findings.
Trial sequential analysis
Our Trial sequential analysis (TSA) showed a very promising strength with 77% power with total sample size of 4,939 AIS patients and 55% power for the studies with 3,062 HS subjects. TSA plot are represented in Figures 4A,B. The high power of the TSA suggests that the meta-analysis is unlikely to be influenced by chance or random fluctuations in the data. Overall, the TSA results provide strong evidence that the meta-analysis is well-powered and that the findings are reliable and generalizable. This reinforces the importance of considering troponin elevation as a crucial factor in risk stratification and treatment decisions for patients with acute stroke.
Figure 4
Discussion
Our findings highlights the significance of routinely assessing admission cTn in stroke patients, emphasizing its association with higher mortality rates. Existing literature has consistently reported the association between elevated troponin levels and all-cause mortality across various stroke types (10, 12). Studies have shown that baseline troponin levels predict poor outcomes in both in-hospital and last follow-up scenarios, irrespective of acute coronary syndrome (69, 71, 72). Furthermore, higher blood troponin levels during the acute phase of acute spontaneous ICH are linked with unfavorable outcomes (69, 71, 72). Similar findings are observed in patients with spontaneous subarachnoid hemorrhage, where an increased risk of cerebral ischemia and death is demonstrated (13, 14, 60).
The current meta-analysis supports and reinforces these findings, indicating that elevated troponin levels serve as predictors for both in-hospital and follow-up mortalities for AIS with additional finding of other subtypes of stroke including SAH and ICH. Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality and last follow-up mortality in both AIS as well as SAH. However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients. However, itās crucial to note that this observation may be influenced by the limited inclusion of only seven studies in the overall analysis.
Previous findings have reported that elevation of cardiac troponin has been reported to occur in ICH patients along with only 1.2% of them died of cardiac causes (69). Although previous studies have been tried to address hypothesis that elevated cardiac troponin might serve as prognostic markers for prediction of adverse clinical events, the results were largely inconsistent and inconclusive with regard to ICH. The previous study demonstrated that elevated troponin levels were associated with higher mortality following ICH (69). Subsequently, the utility of elevated troponin levels for prediction of mortality was confirmed in surgical ICH patients (74), but was not found to be consistently associated with in-hospital mortality in Chinese ICH patients (71). Small sample sizes (less than 240 stroke patients) and ethnic variability probably contribute to the negative results and discrepancies. Similarly in our meta-analysis, only seven ICH studies were included and we observed non-significant association with the elevated level of Troponin.
Approximately 18%ā20% (75ā77) of ischemic stroke patients present with elevated high-sensitive Troponin T (hsTnT) levels on admission, which can be attributed to various factors including renal failure, chronic heart failure, myocardial infarction (MI), and stress-related cardiomyopathies such as neurogenic stunned myocardium (NSM). NSM, characterized by contraction band necrosis at the cellular level, manifests with elevated hsTnT levels and electrocardiographic abnormalities (78ā81). While some patients can be differentiated using ECG and echocardiography, overlap in diagnostic criteria complicates diagnosis for others. Despite common assumptions in stroke centers, attributing elevated hsTnT levels solely to brain or heart origin may not always hold true, as MI patients have an increased risk of stroke (82), even with marginally elevated hsTnT levels, raising questions about predictive value in differentiating NSM from MI (83).
As per the 2023 Guideline for the Management of Patients with SAH by AHA/ASA (84), certain medical parameters, such as BMI, hypertension, hyperglycemia, troponin levels, hyperthermia, peak white blood cell count, C-reactive protein, and high neutrophil counts, have been linked to clinical outcomes in SAH. However, it is emphasized that additional investigation is necessary to determine their prognostic value and influence on treatment outcomes. Furthermore, the guideline underscores the active exploration of novel biomarkers, encompassing imaging, serum, and cerebrospinal fluid (CSF), in the field of SAH. Ongoing research incorporating advanced proteomic, genomic, and other biological marker methods, in conjunction with existing clinical, radiographic, and physiological monitoring data, is deemed essential. These efforts aim to shed light on the potential use of biomarkers for prognosis and interventions, ultimately contributing to improved outcomes in patients with SAH.
The COVID-19 pandemic has placed unprecedented strain on stroke services globally, disrupting healthcare delivery and raising concerns about its impact on stroke outcomes (85). Despite these challenges, our meta-analysis did not identify any explicit instances linking the pandemic with influential impacts on stroke management or patient outcomes across included studies. This highlights the need for further research to understand the nuanced interplay between COVID-19 and stroke care delivery, while also emphasizing the importance of developing adaptive strategies and fostering interdisciplinary collaborations to mitigate the pandemicās adverse effects on stroke services and ensure optimal patient care.
Clinical decision-making regarding troponin elevations in stroke patients is a multifaceted challenge that requires careful consideration of various factors. While elevated troponin levels in stroke patients can indicate myocardial injury, termed ātroponitis,ā itās essential to recognize that other contributing factors such as stress, sepsis, or renal dysfunction may also lead to troponin elevation, particularly in the acute phase of a stroke (86). Therefore, clinicians must conduct a thorough evaluation to differentiate between myocardial infarction and other causes of troponin elevation (87). This evaluation typically involves a comprehensive clinical assessment, including medical history, physical examination, electrocardiography, and imaging studies such as echocardiography or cardiac MRI (88).
Additionally, clinicians may utilize risk stratification tools or algorithms specific to stroke patients with troponin elevations to guide further diagnostic and therapeutic interventions. Collaboration between neurologists, cardiologists, and other specialists is crucial in developing a cohesive management plan tailored to the individual patientās needs, balancing the risks and benefits of interventions such as antiplatelet therapy, anticoagulation, or coronary angiography (89). Ultimately, the decision-making process should prioritize patient safety, optimizing outcomes, and improving overall care in stroke units. Ongoing research and consensus guidelines from professional societies play a vital role in informing evidence-based practices and advancing our understanding of troponin elevations in stroke patients.
Study limitations
While the study has strengths, it acknowledges limitations, including: (1) using a single baseline cTn assessment time point and non-standardized measurement procedures, potentially introducing misclassification; (2) lacking information on important confounders like infarction locations, stroke severity, time from symptom onset, and type of recanalization therapies, which could bias the relationship between elevated cTn and mortality; (3) absence of data on functional outcomes like the modified Rankin Scale; and (4) variations in cut-off values, assay methods, and follow-up periods across individual studies contributed to high heterogeneity from pooled analysis by troponin assays, complicating result interpretation.
Conclusion
Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
AG: Writing ā review & editing, Writing ā original draft, Methodology, Data curation. MS: Investigation, Writing ā review & editing, Methodology, Data curation, Project administration. PK: Writing ā review & editing, Writing ā original draft, Supervision, Software, Formal analysis, Conceptualization.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1351925/full#supplementary-material
References
1.
TadiPLuiF. Acute Stroke In: StatPearls. Treasure Island (FL): StatPearls Publishing (2023)
2.
Roman-FilipCCatanÄM-GMihÄilÄR-G. Prognostic markers for ischemic strokeāare they truly reliable?Med Pharm Rep. (2023) 96:65ā70. doi: 10.15386/mpr-2365
3.
SaceleanuVMToaderCPlesHCovache-BusuiocRACostinHPBratuBGet al. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. (2023) 11:2617. doi: 10.3390/biomedicines11102617
4.
WetterstenNMaiselA. Role of cardiac troponin levels in acute heart failure. Card Fail Rev. (2015) 1:102ā6. doi: 10.15420/cfr.2015.1.2.102
5.
GrefkesCFinkGR. Recovery from stroke: current concepts and future perspectives. Neurol Res Pract. (2020) 2:17. doi: 10.1186/s42466-020-00060-6
6.
FanYJiangMGongDManCChenY. Cardiac troponin for predicting all-cause mortality in patients with acute ischemic stroke: a meta-analysis. Biosci Rep. (2018) 38:BSR20171178. doi: 10.1042/BSR20171178
7.
BohrAMemarzadehK. The rise of artificial intelligence in healthcare applications. Artif Intell Healthc. (2020) 25ā60:2. doi: 10.1016/B978-0-12-818438-7.00002-2
8.
AbdiSOveis-GharanSSinaeiFGhorbaniA. Elevated troponin T after acute ischemic stroke: association with severity and location of infarction. Iran J Neurol. (2015) 14:35ā40. PMID:
9.
EtgenTBaumHSanderKSanderD. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke. (2005) 36:270ā5. doi: 10.1161/01.STR.0000151364.19066.a1
10.
AlhazzaniAKumarAAlgahtanyMRawatD. Role of troponin as a biomarker for predicting outcome after ischemic stroke. Brain Circ. (2021) 7:77ā84. doi: 10.4103/bc.bc_51_20
11.
BroersenLHAStenglHNolteCHWestermannDEndresMSiegerinkBet al. Association between high-sensitivity cardiac troponin and risk of stroke in 96 702 individuals: a Meta-analysis. Stroke. (2020) 51:1085ā93. doi: 10.1161/STROKEAHA.119.028323
12.
DousGVGrigosACGrodmanR. Elevated troponin in patients with acute stroke ā is it a true heart attack?Egypt Heart J. (2017) 69:165ā70. doi: 10.1016/j.ehj.2017.01.005
13.
Memar MontazerinSChiGMarandiRNajafiHShojaeiFLeeJJet al. Evaluation of cardiac troponin and adverse outcomes after aneurysmal subarachnoid hemorrhage: a systematic review and Meta-analysis. Neurocrit Care. (2022) 36:650ā61. doi: 10.1007/s12028-021-01368-0
14.
ZhangLWangZQiS. Cardiac troponin elevation and outcome after subarachnoid hemorrhage: a systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2015) 24:2375ā84. doi: 10.1016/j.jstrokecerebrovasdis.2015.06.030
15.
ZhangYOuyangMQiuJCaoXXuBSuiY. Prognostic value of serum cardiac troponin in acute ischemic stroke: an updated systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2022) 31:106444. doi: 10.1016/j.jstrokecerebrovasdis.2022.106444
16.
LippiGCervellinGSanchis-GomarF. Predicting mortality with cardiac troponins: recent insights from meta-analyses. Diagnosi. (2021) 8:37ā49. doi: 10.1515/dx-2019-0061
17.
PitliyaAAlEdaniEMBhanguJKJavedKManshahiaPKNaharSet al. The impact of elevated troponin levels on clinical outcomes in patients with acute ischemic stroke: a systematic review. Ann Indian Acad Neurol. (2023) 26:641ā54. doi: 10.4103/aian.aian_567_23
18.
CumpstonMLiTPageMJChandlerJWelchVAHigginsJPet al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. (2019) 10:ED000142. doi: 10.1002/14651858.ED000142
19.
MoherDShamseerLClarkeMGhersiDLiberatiAPetticrewMet al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. (2015) 4:1. doi: 10.1186/2046-4053-4-1
20.
StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25:603ā5. doi: 10.1007/s10654-010-9491-z
21.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088ā101. doi: 10.2307/2533446
22.
EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629ā34. doi: 10.1136/bmj.315.7109.629
23.
JamesP. Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ. (2000) 320:1502ā4. doi: 10.1136/bmj.320.7248.1502
24.
TroĆøyenMIndredavikB. Myocardial damage in acute stroke assessed with troponin I. Tidsskr Nor Laegeforen. (2001) 121:421ā5.
25.
Di AngelantonioE. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. (2005) 76:76ā81. doi: 10.1136/jnnp.2004.041491
26.
BarberMMortonJJMacfarlanePWBarlowNRoditiGStottDJ. Elevated troponin levels are associated with Sympathoadrenal activation in acute Ischaemic stroke. Cerebrovasc Dis. (2007) 23:260ā6. doi: 10.1159/000098325
27.
JensenJKKristensenSRBakSAtarDHĆøilund-CarlsenPFMickleyH. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. (2007) 99:108ā12. doi: 10.1016/j.amjcard.2006.07.071
28.
SandhuRAronowWSRajdevASukhijaRAminHD'aquilaKet al. Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Am J Cardiol. (2008) 102:632ā4. doi: 10.1016/j.amjcard.2008.04.036
29.
HajdinjakEKlemenPGrmecÅ . Prognostic value of a single prehospital measurement of N-terminal pro-brain natriuretic peptide and troponin T after acute Ischaemic stroke. J Int Med Res. (2012) 40:768ā76. doi: 10.1177/147323001204000243
30.
ScheitzJFEndresMMochmannH-CAudebertHJNolteCH. Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. Int J Cardiol. (2012) 157:239ā42. doi: 10.1016/j.ijcard.2012.01.055
31.
JensenJKUelandTAukrustPAntonsenLKristensenSRJanuzziJLet al. Highly sensitive troponin T in patients with acute ischemic stroke. Eur Neurol. (2012) 68:287ā93. doi: 10.1159/000341340
32.
Beaulieu-BoireILeblancNBergerLBoulangerJ-M. Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. J Stroke Cerebrovasc Dis. (2013) 22:978ā83. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.008
33.
StahrenbergRNiehausCFEdelmannFMendeMWohlfahrtJWasserKet al. High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia. J Neurol Neurosurg Psychiatry. (2013) 84:479ā87. doi: 10.1136/jnnp-2012-303360
34.
ScheitzJFMochmannHCErdurHTütüncüSHaeuslerKGGrittnerUet al. Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: analyses from the TRELAS cohort. Int J Cardiol. (2014) 177:886ā93. doi: 10.1016/j.ijcard.2014.10.036
35.
Lasek-BalAKowalewska-TwardelaTGÄ siorZWarsz-WianeckaAHaberkaMPuzPet al. The significance of troponin elevation for the clinical course and outcome of first-ever Ischaemic stroke. Cerebrovasc Dis. (2014) 38:212ā8. doi: 10.1159/000365839
36.
FaizKWThommessenBEinvikGBrekkePHOmlandTRĆønningOM. Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke. BMC Neurol. (2014) 14:96. doi: 10.1186/1471-2377-14-96
37.
RazaFAlkhouliMSandhuPBhattRBoveAA. Elevated cardiac troponin in acute stroke without acute coronary syndrome predicts long-term adverse cardiovascular outcomes. Stroke Res Treat. (2014) 2014:1ā6. doi: 10.1155/2014/621650
38.
BatalOJentzerJBalaneyBKoliaNHickeyGDardariZet al. The prognostic significance of troponin I elevation in acute ischemic stroke. J Crit Care. (2016) 31:41ā7. doi: 10.1016/j.jcrc.2015.09.018
39.
MaozARosenbergSLekerRR. Increased high-sensitivity troponin-T levels are associated with mortality after ischemic stroke. J Mol Neurosci. (2015) 57:160ā5. doi: 10.1007/s12031-015-0593-7
40.
SuY-CHuangK-FYangF-YLinS-K. Elevation of troponin I in acute ischemic stroke. PeerJ. (2016) 4:e1866. doi: 10.7717/peerj.1866
41.
BudincevicHSremecJCrnacPOstojicVGalicEBielenI. Impact of troponin I on outcome of ischemic stroke patients. Rom J Intern Med. (2017) 55:19ā22. doi: 10.1515/rjim-2016-0044
42.
PeddadaKCruz-FloresSGoldsteinLBFeenEKennedyKFHeuringTet al. Ischemic stroke with troponin elevation: patient characteristics, resource utilization, and in-hospital outcomes. Cerebrovasc Dis. (2016) 42:213ā23. doi: 10.1159/000445526
43.
AkpinarO. Prognostic value of troponin t in patients with acute ischemic stroke in EMERGENCY department. Acta Medica Mediterr. (2017) 757ā761:111. doi: 10.19193/0393-6384_2017_5_111
44.
WrigleyPKhouryJEckerleBAlwellKMoomawCJWooDet al. Prevalence of positive troponin and echocardiogram findings and association with mortality in acute ischemic stroke. Stroke. (2017) 48:1226ā32. doi: 10.1161/STROKEAHA.116.014561
45.
AhnS-HLeeJSKimYHKimBJKimYJKangDWet al. Prognostic significance of troponin elevation for long-term mortality after ischemic stroke. J Stroke. (2017) 19:312ā22. doi: 10.5853/jos.2016.01942
46.
FathyHAAshourWMRElserafyTSAmerMM. The prognostic value of elevated cardiac troponin-I in short-term outcome of acute ischemic stroke. Int J Clin Exp Neurol. (2018) 6:1ā7.
47.
HeLWangJDongW. The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. BMC Neurol. (2018) 18:118. doi: 10.1186/s12883-018-1121-5
48.
AhnS-HKimYHLeeJSHanJHKimSYKangDWet al. Troponin I levels and long-term outcomes in acute ischemic stroke patients. J Am Coll Cardiol. (2019) 73:525ā6. doi: 10.1016/j.jacc.2018.11.022
49.
HeMPanchangamSCruzBMukherjeeD. Underutilization of cardiac therapies in patients with acute ischemic stroke and elevated troponin. Cardiovasc Hematol Agents Med Chem. (2019) 17:144ā51. doi: 10.2174/1871525717666191019115338
50.
TerceñoMSilvaYBashirSVera-MongeVBuxóMSerenaJ. Troponin T predicts Cardioembolic Aetiology and clinical outcome in undetermined Ischaemic stroke in Hyperacute phase. J Stroke Cerebrovasc Dis. (2020) 29:104528. doi: 10.1016/j.jstrokecerebrovasdis.2019.104528
51.
SuiYLiuTLuoJXuBZhengLZhaoWet al. Elevation of high-sensitivity cardiac troponin T at admission is associated with increased 3-month mortality in acute ischemic stroke patients treated with thrombolysis. Clin Cardiol. (2019) 42:881ā8. doi: 10.1002/clc.23237
52.
CaoY-ZZhaoLBLiuSLiuQHJiangLZhouCGet al. Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with acute ischemic stroke treated with endovascular thrombectomy. J Clin Neurosci. (2019) 64:145ā9. doi: 10.1016/j.jocn.2019.03.030
53.
AlkhachroumAMMillerBChamiTTatsuokaCSilaC. A troponin study on patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage: type II myocardial infarction is significantly associated with stroke severity, discharge disposition and mortality. J Clin Neurosci. (2019) 64:83ā8. doi: 10.1016/j.jocn.2019.04.005
54.
ThapaPAgrawalJPBaniyaR. A study on elevation of troponin I in ischemic stroke as an independent prognostic marker of outcomes. Nepal J Neurosci. (2020) 17:26ā34. doi: 10.3126/njn.v17i2.30224
55.
ScheitzJFStenglHNolteCHLandmesserUEndresM. Neurological update: use of cardiac troponin in patients with stroke. J Neurol. (2021) 268:2284ā92. doi: 10.1007/s00415-020-10349-w
56.
NageebRSOmranAAMohamedWS. Troponin-I elevation predicts outcome after thrombolysis in ischemic stroke patients. Egypt J Neurol Psychiatry Neurosurg. (2021) 57:4. doi: 10.1186/s41983-020-00256-2
57.
MirajAAMohammadQDRahmanSMiahS. Elevation of troponin I in ischemic stroke of outcomes in patients with acute stroke. Acute Stroke Br J Res. (2022) 9:120. doi: 10.21767/2394-3718.9.12.120
58.
ChenFBaiXWangXZhangLWangFHuangLet al. Impact of high-sensitivity troponin elevation and dynamic changes on 90-day mortality in patients with acute ischemic stroke after mechanical thrombectomy: results from an observational cohort. J NeuroInterventional Surg. (2022) 15:1142ā7. doi: 10.1136/jnis-2022-019682
59.
KimBSParkJJChangHKimSHKwonCHChungSMet al. Association of High-Sensitivity Troponin I with cardiac and cerebrovascular events in patient after ischemic stroke. Cerebrovasc Dis. (2023) 52:153ā9. doi: 10.1159/000525920
60.
DeibertEBarzilaiBBravermanACEdwardsDFAiyagariVDaceyRet al. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. J Neurosurg. (2003) 98:741ā6. doi: 10.3171/jns.2003.98.4.0741
61.
NaidechAMKreiterKTJanjuaNOstapkovichNDParraACommichauCet al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. (2005) 112:2851ā6. doi: 10.1161/CIRCULATIONAHA.105.533620
62.
RamappaPThataiDCoplinWGellmanSCarhuapomaJRQuahRet al. Cardiac troponin-I: a predictor of prognosis in subarachnoid hemorrhage. Neurocrit Care. (2008) 8:398ā403. doi: 10.1007/s12028-007-9038-7
63.
GupteMJohnSPrabhakaranSLeeVH. Troponin elevation in subarachnoid hemorrhage does not impact in-hospital mortality. Neurocrit Care. (2013) 18:368ā73. doi: 10.1007/s12028-012-9813-y
64.
DuelloKMNagelJPThomasCSBlackshearJLFreemanWD. Relationship of troponin T and age- and sex-adjusted BNP elevation following subarachnoid hemorrhage with 30-day mortality. Neurocrit Care. (2015) 23:59ā65. doi: 10.1007/s12028-014-0105-6
65.
GuettePLauneyYArnouatMBleichnerJPMasseretERousseauCet al. Prognostic value of high-sensitivity troponin T in aneurysmal subarachnoid hemorrhage: a prospective observational study. Brain Inj. (2019) 33:1372ā8. doi: 10.1080/02699052.2019.1641742
66.
AkkermansAPeelenLMVan WaesJARinkelGJVan KleiWA. Cardiac events within one year after a subarachnoid haemorrhage: the predictive value of troponin elevation after aneurysm occlusion. Eur J Prev Cardiol. (2019) 26:420ā8. doi: 10.1177/2047487318776098
67.
LinFChenYHeQZengCZhangCChenXet al. Prognostic value of elevated cardiac troponin I after aneurysmal subarachnoid hemorrhage. Front Neurol. (2021) 12:677961. doi: 10.3389/fneur.2021.677961
68.
AnetsbergerAJungwirthBBlobnerMRingelFBernlochnerIHeimMet al. Association of Troponin T levels and functional outcome 3 months after subarachnoid hemorrhage. Sci Rep. (2021) 11:16154. doi: 10.1038/s41598-021-95717-w
69.
HaysADiringerMN. Elevated troponin levels are CME associated with higher mortality following intracerebral hemorrhage. Neurology. (2006) 66:1330ā4. doi: 10.1212/01.wnl.0000210523.22944.9b
70.
ChungP-WWonYSKwonYJChoiCSKimBM. Initial troponin level as a predictor of prognosis in patients with intracerebral hemorrhage. J Korean Neurosurg Soc. (2009) 45:355ā9. doi: 10.3340/jkns.2009.45.6.355
71.
XuMLinJWangDLiuMHaoZLeiC. Cardiac troponin and cerebral herniation in acute intracerebral hemorrhage. Brain Behav. (2017) 7:e00697. doi: 10.1002/brb3.697
72.
GernerSTAuerbeckKSprügelMISembillJAMadžarDGƶlitzPet al. Peak troponin I levels are associated with functional outcome in intracerebral hemorrhage. Cerebrovasc Dis. (2018) 46:72ā81. doi: 10.1159/000492395
73.
HeYLiuQWangJWangDWDingHWangW. Prognostic value of elevated cardiac troponin I in patients with intracerebral hemorrhage. Clin Cardiol. (2020) 43:338ā45. doi: 10.1002/clc.23320
74.
GarrettMCKomotarRJStarkeRMDoshiDOttenMLConnollyES. Elevated troponin levels are predictive of mortality in surgical intracerebral hemorrhage patients. Neurocrit Care. (2010) 12:199ā203. doi: 10.1007/s12028-009-9245-5
75.
AndersBAlonsoAArtemisDSchƤferAEbertAKablauMet al. What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients?Cerebrovasc Dis. (2013) 36:211ā7. doi: 10.1159/000353875
76.
DarkiASchneckMJAgrawalARupaniABarronJT. Correlation of elevated troponin and echocardiography in acute ischemic stroke. J Stroke Cerebrovasc Dis. (2013) 22:959ā61. doi: 10.1016/j.jstrokecerebrovasdis.2011.12.004
77.
KerrGRayGWuOStottDJLanghorneP. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis. (2009) 28:220ā6. doi: 10.1159/000226773
78.
NguyenHZaroffJG. Neurogenic stunned myocardium. Curr Neurol Neurosci Rep. (2009) 9:486ā91. doi: 10.1007/s11910-009-0071-0
79.
DombrowskiKLaskowitzD. Cardiovascular manifestations of neurologic disease. Handb Clin Neurol. (2014) 119:3ā17. doi: 10.1016/B978-0-7020-4086-3.00001-1
80.
ApakIIltumurKTamamYKayaN. Serum cardiac troponin T levels as an indicator of myocardial injury in ischemic and hemorrhagic stroke patients. Tohoku J Exp Med. (2005) 205:93ā101. doi: 10.1620/tjem.205.93
81.
MazzeoATMicalizziAMasciaLScicoloneASiracusanoL. Brain-heart crosstalk: the many faces of stress-related cardiomyopathy syndromes in anaesthesia and intensive care. Br J Anaesth. (2014) 112:803ā15. doi: 10.1093/bja/aeu046
82.
VisserCAKanGLieKIDurrerD. Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. Eur Heart J. (1983) 4:333ā7. doi: 10.1093/oxfordjournals.eurheartj.a061470
83.
HeldnerMRPilgrimTWustmannKHsiehKMattleHPArnoldMet al. Acute carotid T occlusion in a young patient: cryptogenic origin?Stroke. (2014) 45:e125ā7. doi: 10.1161/STROKEAHA.114.005388
84.
HohBLKoNUAmin-HanjaniSChouSH-YCruz-FloresSDangayachNSet al. 2023 guideline for the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. (2023) 54:e314ā70. doi: 10.1161/STR.0000000000000436
85.
SmallCMehkriYPantherEFelismaPLucke-WoldB. Coronavirus Disease-2019 and stroke: pathophysiology and management. Can J Neurol Sci J Can Sci Neurol. (2023) 50:495ā502. doi: 10.1017/cjn.2022.267
86.
van BeekDECvan der HorstICCScheerenTWL. Troponin elevations after cardiac surgery: just āTroponitisā? In: VincentJ-L, editor. Annual update in intensive care and Emergency medicine 2020. Cham: Springer International Publishing (2020). 113ā24.
87.
BodyRCarltonE. Understanding cardiac troponin part 1: avoiding troponinitis. Emerg Med J EMJ. (2018) 35:120ā5. doi: 10.1136/emermed-2017-206812
88.
KorffSKatusHAGiannitsisE. Differential diagnosis of elevated troponins. Heart. (2006) 92:987ā93. doi: 10.1136/hrt.2005.071282
89.
AlaourBLiewFKaierTE. Cardiac troponinādiagnostic problems and impact on cardiovascular disease. Ann Med. (2018) 50:655ā65. doi: 10.1080/07853890.2018.1530450
Summary
Keywords
troponin, mortality, acute stroke, ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage
Citation
Gulia A, Srivastava M and Kumar P (2024) Elevated troponin levels as a predictor of mortality in patients with acute stroke: a systematic review and meta-analysis. Front. Neurol. 15:1351925. doi: 10.3389/fneur.2024.1351925
Received
07 December 2023
Accepted
29 February 2024
Published
25 March 2024
Volume
15 - 2024
Edited by
Faraz Rashid, Henry Ford Health System, United States
Reviewed by
Brandon Peter Lucke-Wold, University of Florida, United States
Robert Daniel Nass, University Hospital Bonn, Germany
Updates
Copyright
Ā© 2024 Gulia, Srivastava and Kumar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pradeep Kumar, pradeepguptaneuro@gmail.com; pradeepgupta@aiims.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.